Statistical methods for building better biomarkers of chronic kidney disease
dc.contributor.author | Pencina, Michael J. | |
dc.contributor.author | Parikh, Chirag R. | |
dc.contributor.author | Kimmel, Paul L. | |
dc.contributor.author | Cook, Nancy R. | |
dc.contributor.author | Coresh, Josef | |
dc.contributor.author | Feldman, Harold I. | |
dc.contributor.author | Foulkes, Andrea | |
dc.contributor.author | Gimotty, Phyllis A. | |
dc.contributor.author | Hsu, Chi‐yuan | |
dc.contributor.author | Lemley, Kevin | |
dc.contributor.author | Song, Peter | |
dc.contributor.author | Wilkins, Kenneth | |
dc.contributor.author | Gossett, Daniel R. | |
dc.contributor.author | Xie, Yining | |
dc.contributor.author | Star, Robert A. | |
dc.date.accessioned | 2019-05-31T18:26:24Z | |
dc.date.available | 2020-07-01T17:47:46Z | en |
dc.date.issued | 2019-05-20 | |
dc.identifier.citation | Pencina, Michael J.; Parikh, Chirag R.; Kimmel, Paul L.; Cook, Nancy R.; Coresh, Josef; Feldman, Harold I.; Foulkes, Andrea; Gimotty, Phyllis A.; Hsu, Chi‐yuan ; Lemley, Kevin; Song, Peter; Wilkins, Kenneth; Gossett, Daniel R.; Xie, Yining; Star, Robert A. (2019). "Statistical methods for building better biomarkers of chronic kidney disease." Statistics in Medicine 38(11): 1903-1917. | |
dc.identifier.issn | 0277-6715 | |
dc.identifier.issn | 1097-0258 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/149268 | |
dc.publisher | Division of Drug Information, Office of Communications, Center for Drug Evaluation and Research (CDER) | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | calibration | |
dc.subject.other | costâ benefit | |
dc.subject.other | discrimination | |
dc.subject.other | risk communication | |
dc.subject.other | risk model | |
dc.subject.other | validation | |
dc.title | Statistical methods for building better biomarkers of chronic kidney disease | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Statistics and Numeric Data | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbsecondlevel | Medicine (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.subject.hlbtoplevel | Science | |
dc.subject.hlbtoplevel | Social Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/149268/1/sim8091.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/149268/2/sim8091_am.pdf | |
dc.identifier.doi | 10.1002/sim.8091 | |
dc.identifier.source | Statistics in Medicine | |
dc.identifier.citedreference | Vickers AJ, Pencina MJ. Prostateâ specific antigen velocity: new methods, same results, still no evidence of clinical utility. Eur Urol. 2013; 64: 394 â 396. | |
dc.identifier.citedreference | Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001; 54: 774 â 781. | |
dc.identifier.citedreference | Pencina MJ, D’Agostino Sr RB. Thoroughly modern risk prediction? Sci Transl Med. 2012; 4:131fs110. | |
dc.identifier.citedreference | Parikh CR, Thiessenâ Philbrook H. Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease. J Am Soc Nephrol. 2014; 25: 1621 â 1629. | |
dc.identifier.citedreference | Collins GS, Reitsma JB, Altman DG, Moons KG. T ransparent r eporting of a multivariable prediction model for i ndividual p rognosis or d iagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015; 162: 55 â 63. | |
dc.identifier.citedreference | Van Calster B, Vickers AJ. Calibration of risk prediction models: impact on decisionâ analytic performance. Med Dec Making. 2015; 35: 162 â 169. | |
dc.identifier.citedreference | Sniderman AD, Pencina M, Thanassoulis G. Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk. Curr Opin Lipidol. 2015; 26: 210 â 214. | |
dc.identifier.citedreference | Holland PW. Causal inference, path analysis, and recursive structural equation models (with discussion). Sociol Methodol. 1988; 18: 449 â 484. | |
dc.identifier.citedreference | Imai K, Tingley D, Yamamoto T. Experimental designs for identifying causal mechanisms. J R Stat Soc A Stat Soc. 2013; 176: 5 â 51. | |
dc.identifier.citedreference | Steyerberg EW, Vedder MM, Leening MJ, et al. Graphical assessment of incremental value of novel markers in prediction models: from statistical to decision analytical perspectives. Biom J Biom Z. 2015; 57: 556 â 570. | |
dc.identifier.citedreference | Hedeker DR, Gibbons RD. Longitudinal Data Analysis. Hoboken, NJ: Wileyâ Interscience; 2006. | |
dc.identifier.citedreference | Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc. 1999; 94: 496 â 509. | |
dc.identifier.citedreference | Chapfuwa P, Tao C, Li C, et al. Adversarial timeâ toâ event modelling. Paper presented at: 35th International Conference on Machine Learning; 2018; Stockholm, Sweden. | |
dc.identifier.citedreference | Andersen PK. Statistical Models Based on Counting Processes. New York, NY: Springerâ Verlag; 1993. | |
dc.identifier.citedreference | Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sci USA. 1975; 72: 20 â 22. | |
dc.identifier.citedreference | Van Calster B, Van Belle V, Vergouwe Y, Timmerman D, Van Huffel S, Steyerberg EW. Extending the c â statistic to nominal polytomous outcomes: the Polytomous Discrimination Index. Statist Med. 2012; 31: 2610 â 2626. | |
dc.identifier.citedreference | Li JL, Jiang BY, Fine JP. Multicategory reclassification statistics for assessing improvements in diagnostic accuracy. Biostatistics. 2013; 14: 382 â 394. | |
dc.identifier.citedreference | Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009; 20: 555 â 561. | |
dc.identifier.citedreference | Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and endâ stage renal disease. J Am Med Assoc. 2012; 308: 2349 â 2360. | |
dc.identifier.citedreference | Vedder MM, de Bekkerâ Grob EW, Lilja HG, et al. The added value of percentage of free to total prostateâ specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol. 2014; 66: 1109 â 1115. | |
dc.identifier.citedreference | Rizopoulos D. JM: an R package for the joint modelling of longitudinal and timeâ toâ event data. J Stat Softw. 2010; 35: 1 â 33. | |
dc.identifier.citedreference | Hatfield LA, Carlin BP. Clinically relevant graphical predictions from Bayesian joint longitudinalâ survival models. Health Serv Outcomes Res Meth. 2012; 12: 169 â 181. | |
dc.identifier.citedreference | Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostateâ specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011; 103: 462 â 469. | |
dc.identifier.citedreference | Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncology. 2010; 28: 2796 â 2801. | |
dc.identifier.citedreference | Komarek A, Komarkova L. Clustering for multivariate continuous and discrete longitudinal data. Ann Appl Stat. 2013; 7: 177 â 200. | |
dc.identifier.citedreference | Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006; 145: 176 â 184. | |
dc.identifier.citedreference | Navarâ Boggan AM, Peterson ED, D’Agostino RB, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases longâ term risk of coronary heart disease. Circulation. 2015; 131: 451 â 458. | |
dc.identifier.citedreference | Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JAC. Methods for dealing with timeâ dependent confounding. Statist Med. 2013; 32: 1584 â 1618. | |
dc.identifier.citedreference | Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007; 18: 3164 â 3170. | |
dc.identifier.citedreference | Wang F, Wang L, Song PXK. Quadratic inference function approach to merging longitudinal studies: validation and joint estimation. Biometrika. 2012; 99: 755 â 762. | |
dc.identifier.citedreference | Wang F, Song PX, Wang L. Merging multiple longitudinal studies with studyâ specific missing covariates: a joint estimating function approach. Biometrics. 2015; 71 ( 4 ): 929 â 940. | |
dc.identifier.citedreference | Krumholz HM, Ross JS. A model for dissemination and independent analysis of industry data. J Am Med Assoc. 2011; 306: 1593 â 1594. | |
dc.identifier.citedreference | Institute of Medicine of the National Academies. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: National Academies Press; 2015. | |
dc.identifier.citedreference | Pencina MJ, Louzao DM, McCour BJ, et al. Supporting open access to clinical trial data for researchers: the Duke Clinical Research Instituteâ Bristolâ Myers Squibb supporting open access to researchers initiative. Am Heart J. 2016; 172: 64 â 69. | |
dc.identifier.citedreference | US National Institutes of Health. HHS and NIH take steps to enhance transparency of clinical trial results. 2014. | |
dc.identifier.citedreference | Lo B. Sharing clinical trial data maximizing benefits, minimizing risk. J Am Med Assoc. 2015; 313: 793 â 794. | |
dc.identifier.citedreference | Detilleux J, Reginster JY, Chines A, Bruyere O. A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through nonâ linear changes in bone mass density. Stat Meth Med Res. 2012; 25 ( 1 ): 400 â 412. | |
dc.identifier.citedreference | Roysland K, Gran JM, Ledergerber B, von Wyl V, Young J, Aalen OO. Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV cohort study. Statist Med. 2011; 30: 2947 â 2958. | |
dc.identifier.citedreference | Winship C, Mare RD. Structural equations and path analysis for discrete data. Am J Sociol. 1983; 89: 54 â 110. | |
dc.identifier.citedreference | Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119: 2408 â 2416. | |
dc.identifier.citedreference | US Food and Drug Administration. Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. Silver Spring, MD: Division of Drug Information, Office of Communications, Center for Drug Evaluation and Research (CDER); 2014. | |
dc.identifier.citedreference | Sniderman AD, D’Agostino RB, Pencina MJ. The role of physicians in the era of predictive analytics. J Am Med Assoc. 2015; 314: 25 â 26. | |
dc.identifier.citedreference | Demler OV, Pencina MJ, D’Agostino RB. Misuse of DeLong test to compare AUCs for nested models. Statist Med. 2012; 31: 2577 â 2587. | |
dc.identifier.citedreference | Pepe MS, Kerr KF, Longton G, Wang Z. Testing for improvement in prediction model performance. Statist Med. 2013; 32: 1467 â 1482. | |
dc.identifier.citedreference | Vickers AJ, Pepe M. Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med. 2014; 160: 136â 137. | |
dc.identifier.citedreference | Harrell FE. Regression Modeling Strategies. New York, NY: Springer; 2015. | |
dc.identifier.citedreference | Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010; 21: 128 â 138. | |
dc.identifier.citedreference | Baker SG, Cook NR, Vickers A, Kramer BS. Using relative utility curves to evaluate risk prediction. J R Stat Soc A Stat Soc. 2009; 172: 729 â 748. | |
dc.identifier.citedreference | Van Calster B, Vickers AJ, Pencina MJ, Bake SG, Timmerman D, Steyerberg EW. Evaluation of markers and risk prediction models: overview of relationships between NRI and decisionâ analytic measures. Med Decis Making. 2013; 33: 490 â 501. | |
dc.identifier.citedreference | Chambless LE, Diao G. Estimation of timeâ dependent area under the ROC curve for longâ term risk prediction. Statist Med. 2006; 25: 3474 â 3486. | |
dc.identifier.citedreference | Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statist Med. 2004; 23: 2109 â 2123. | |
dc.identifier.citedreference | Kerr KF, McClelland RL, Brown ER, Lumley T. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol. 2011; 174: 364 â 374. | |
dc.identifier.citedreference | Tjur T. Coefficients of determination in logistic regression modelsâ A new proposal: the coefficient of discrimination. Am Stat. 2009; 63: 366 â 372. | |
dc.identifier.citedreference | Korn EL, Simon R. Measures of explained variation for survival data. Statist Med. 1990; 9: 487 â 503. | |
dc.identifier.citedreference | Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355: 2631 â 2639. | |
dc.identifier.citedreference | Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008; 358: 2107 â 2116. | |
dc.identifier.citedreference | Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a caseâ mix effect from incorrect coefficients. Am J Epidemiol. 2010; 172: 971 â 980. | |
dc.identifier.citedreference | White IR, Rapsomaniki E. Covariateâ adjusted measures of discrimination for survival data. Biom J. 2015; 57: 592 â 613. | |
dc.identifier.citedreference | Pepe MS, Fan J, Seymour CW, Li C, Huang Y, Feng Z. Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem. 2012; 58: 1242 â 1251. | |
dc.identifier.citedreference | Siontis GC, Tzoulaki I, Castaldi PJ, Ioannidis JP. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. J Clin Epidemiol. 2015; 68: 25 â 34. | |
dc.identifier.citedreference | Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115: 928 â 935. | |
dc.identifier.citedreference | Hand DJ. Measuring classifier performance: a coherent alternative to the area under the ROC curve. Mach Learn. 2009; 77: 103 â 123. | |
dc.identifier.citedreference | Hilden J. The area under the ROC curve and its competitors. Med Decis Making. 1991; 11: 95 â 101. | |
dc.identifier.citedreference | Yates JF. External correspondence: decompositions of the mean probability score. Organ Behav Hum Perf. 1982; 30: 132 â 156. | |
dc.identifier.citedreference | Pencina MJ, D’Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012; 176: 473 â 481. | |
dc.identifier.citedreference | Pencina MJ, D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med. 2008; 27: 157 â 172. | |
dc.identifier.citedreference | Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest. 2012; 42: 216 â 228. | |
dc.identifier.citedreference | Bansal A, Pepe MS. When does combining markers improve classification performance and what are implications for practice? Statist Med. 2013; 32: 1877 â 1892. | |
dc.identifier.citedreference | Demler OV, Pencina MJ, D’Agostino RB. Impact of correlation on predictive ability of biomarkers. Statist Med. 2013; 32: 4196 â 4210. | |
dc.identifier.citedreference | Demler OV, Paynter NP, Cook NR. Tests of calibration and goodnessâ ofâ fit in the survival setting. Statist Med. 2015; 34: 1659 â 1680. | |
dc.identifier.citedreference | Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011; 173: 1327 â 1335. | |
dc.identifier.citedreference | Moons KG, Altman DG, Reitsma JB, et al. T ransparent r eporting of a multivariable prediction model for i ndividual p rognosis or d iagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015; 162: W1 â W73. | |
dc.identifier.citedreference | Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996; 15: 361 â 387. | |
dc.identifier.citedreference | Kerr KF, Meisner A, Thiessenâ Philbrook H, Coca SG, Parikh CR. Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers. Clin J Am Soc Nephrol. 2014; 9: 1488 â 1496. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.